COMPASS Sets Course For J&J/Bayer's Xarelto In Unexplored Indications
A large new market in coronary artery and peripheral arterial disease beckons after Xarelto showed a 24% reduction in the risk of major cardiac events, a benefit that may outweigh the increase in major bleeding.
You may also be interested in...
The German group has been talking up its pharmaceuticals division but analysts are not convinced it has addressed the elephant in the room that is the loss of patent protection for its blockbuster anticoagulant Xarelto in 2024.
Keeping Track: Xarelto Earns CV Risk Reduction Claim In Quiet Week; Spotlight On Formal Dispute Resolution
Latest drug development news and highlights from our US FDA Performance Tracker
Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."